Abstract
TLR4/MD-2, a protein complex to recognize LPS, has become an ideal target for the treatment of inflammation-related diseases. Blumeatin (BL), which is isolated from Blumea balsamifera (L.) DC has rarely been reported in the inflammation field. In this article, we targeted the TLR4/MD-2 complex to explore how BL regulates the TLR4/NF-κB inflammatory signaling pathway and inhibits LPS-induced inflammation. BL can target the hydrophobic pocket of TLR4/MD-2, inhibit the binding of LPS to TLR4/MD-2, the dimerization of TLR4 and MD-2, and the TLR4/NF-κB signaling pathway activation and the secretion of downstream inflammatory factors. BL may be used as a molecular target of TLR4/MD-2 for the treatment of inflammation-related diseases.
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have